Endocrinology News and Research

Latest Endocrinology News and Research

Ipsen reports positive initial results from Dysport phase III study in Adult Upper Limb spasticity

Ipsen today announced positive initial results from the double-blind phase III study of Dysport (abobotulinumtoxinA) in Adult Upper Limb spasticity. Regarding the primary endpoints, treatment with Dysport showed statistically significant response versus placebo in the improvement of muscle tone, as measured by the Modified Ashworth Scale.

17 Dec 2013

Minorities who are at highest risk of diabetes may benefit from beverage sugar tax

Taxing sugar-sweetened beverages is likely to decrease consumption, resulting in lower rates of diabetes and heart disease, and these health benefits are expected to be greatest for the low-income, Hispanic and African-American Californians who are at highest risk of diabetes, according to a new analysis led by researchers at UC San Francisco.

17 Dec 2013

Professor wins U.S. Patent for use of antioxidant compound used in treatment of obesity

A Skidmore College alumnus and professor have been awarded U.S. Patent No. 8,598,150 for use of an antioxidant compound that shows promise in the treatment of obesity and related disorders, such as type-2 diabetes.

17 Dec 2013

Secondary conditions can become deadly and affect how long HIV patients stay in hospital

A University of Arkansas researcher and her colleagues have found that secondary conditions and diseases that could become deadly significantly affect how long HIV patients stay in the hospital.

17 Dec 2013

New commentary documents harmful effects of sequestration on Indian Health Service

As federal legislators work toward a budget agreement, a new commentary documents the harmful effects of sequestration on the Indian Health Service. Sequestration forced a 5 percent reduction in funds for the Indian Health Service, perpetuating longstanding health care disparities and raising questions about the federal government's legal and moral obligation to Indians, states the commentary, which appears in the Hastings Center Report.

17 Dec 2013

Study: Health care costs increase in parallel with body mass measurements

Researchers at Duke Medicine are giving people another reason to lose weight in the new year: obesity-related illnesses are expensive. According to a study published in the journal Obesity, health care costs increase in parallel with body mass measurements, even beginning at a recommended healthy weight.

17 Dec 2013

Study explores how blood sugar levels during pregnancy influence children’s fat

Researchers from Manchester have begun a new study to determine whether blood sugar levels during pregnancy, lower than the level used to diagnose gestational diabetes, influences later levels of body fat in children and development of diabetes in mothers after giving birth.

16 Dec 2013

Potential dual benefits to tackling LUTS progression risk factors

Research shows that several risk factors associated with Type 2 diabetes and cardiovascular disease also predict the progression of storage and voiding lower urinary tract symptoms in men, suggesting that targeting these could have multiple benefits.

16 Dec 2013

Low vitamin D a consequence not a cause of ill health

Low vitamin D status is a marker of ill health rather than an underlying cause of disease, say the authors of a systematic review published in The Lancet Diabetes and Endocrinology.

16 Dec 2013

MicroBiome Therapeutics announces completion of $1.3M bridge financing

MicroBiome TherapeuticsTM LLC, today announced completion of a $1.3 million bridge financing. It is intended to support completion of the company's two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in development for type 2 diabetes and prediabetes. The bridge financing was led by current investor BVM Capital, who was joined in the round by other existing MBT investors.

16 Dec 2013

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen Research & Development, LLC (Janssen) today announced it has received from the U.S. Food and Drug Administration (FDA) a complete response letter regarding its New Drug Application (NDA) for a fixed-dose combination (FDC) of canagliflozin and immediate-release metformin to treat adults with type 2 diabetes.

16 Dec 2013

Diabetes most common among older men and those living in the South

About 8.8 percent of the privately insured population in 2012 had diabetes or was diagnosed as being at high risk for diabetes, up from 8.3 percent in 2011, but the rates of disease varied depending on age, gender and region of the country, says a new report from HCCI. In 2012, over one quarter of men between the ages of 55-64 and nearly one in 10 Southerners had diabetes or were at risk for diabetes.

16 Dec 2013

UTHealth professor wins Founders' Laurel Award for exceptional service in the field of medical education

Arthur L. Day, M.D., professor of neurosurgery at The University of Texas Health Science Center at Houston and a neurosurgeon at the Mischer Neuroscience Institute at Memorial Hermann-Texas Medical Center, has received one of the top honors awarded by the Congress of Neurological Surgeons.

14 Dec 2013

New UCSF-led study links obesity to development of chronic kidney disease

A new UCSF-led study of nearly 3,000 individuals links obesity to the development of kidney disease. The work also shows that, when properly measured, declines in kidney function are detectable long before the emergence of other obesity-related diseases such as diabetes and high blood pressure.

14 Dec 2013

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Genzyme, a Sanofi company, announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis, with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.

13 Dec 2013

Children can reap positive health benefits from increased physical activity

Studies conducted by the Appalachian State University Human Performance Laboratory at the NC Research Campus in Kannapolis, N.C., show that when children increase their level of physical activity, they experience positive health benefits quickly.

13 Dec 2013

Artificial sweetener sucralose has biological effects

The artificial sweetener sucralose is a biologically active compound according to an extensive review published by Taylor & Francis in the recent issue of Journal of Toxicology and Environmental Health, Part B: Critical Reviews. "Sucralose, A Synthetic Organochlorine Sweetener: Overview Of Biological Issues" authored by Susan S. Schiffman, PhD, an internationally known sweetener researcher and Kristina I. Rother, MD, MHSc, of the National Institutes of Health (NIH), summarizes the biological properties of sucralose based on hundreds of archival, peer-reviewed scientific journal publications.

13 Dec 2013

Geriatrician draws specific conclusions about Santa’s health habits

Children around the world look to Santa Claus as a model of good behavior. But can this sleigh-riding bearer of goodies also be a model good health habits for adults?

13 Dec 2013

Texas Children's Heart Center opens Center for Preventive Cardiology

Texas Children's Heart Center is proud to announce the opening of the Center for Preventive Cardiology, which is designed to medically manage the risk factors of acquired heart disease in children. The center is the only one of its kind in Texas that offers multidisciplinary, specialized care for children with these risk factors or who have a strong family history of cardiac disease, elevated cholesterol, high blood pressure or the diagnosis of Kawasaki disease.

13 Dec 2013

Study: Antisense drugs show activity in wide range of tissues and organs

Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional gene and silence its activity. A new study has shown that antisense drugs delivered systemically show activity in a wide range of tissues and organs, supporting their broad therapeutic potential in many disease indications, as described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

13 Dec 2013

Endocrinology News and Research

Latest Endocrinology News and Research

Ipsen reports positive initial results from Dysport phase III study in Adult Upper Limb spasticity

Minorities who are at highest risk of diabetes may benefit from beverage sugar tax

Professor wins U.S. Patent for use of antioxidant compound used in treatment of obesity

Secondary conditions can become deadly and affect how long HIV patients stay in hospital

New commentary documents harmful effects of sequestration on Indian Health Service

Study: Health care costs increase in parallel with body mass measurements

Study explores how blood sugar levels during pregnancy influence children’s fat

Potential dual benefits to tackling LUTS progression risk factors

Low vitamin D a consequence not a cause of ill health

MicroBiome Therapeutics announces completion of $1.3M bridge financing

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Diabetes most common among older men and those living in the South

UTHealth professor wins Founders' Laurel Award for exceptional service in the field of medical education

New UCSF-led study links obesity to development of chronic kidney disease

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Children can reap positive health benefits from increased physical activity

Artificial sweetener sucralose has biological effects

Geriatrician draws specific conclusions about Santa’s health habits

Texas Children's Heart Center opens Center for Preventive Cardiology

Study: Antisense drugs show activity in wide range of tissues and organs

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Endocrinology News and Research

Latest Endocrinology News and Research

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in